BZL Biologics, LLC
- Diagnostic and therapeutic antibodies
BZL Biologics, LLC is developing monoclonal antibodies for diagnostic imaging and therapy for a variety of cancers. Antibodies against prostate-specific membrane antigen (PSMA), developed at Weill Cornell Medicine, were the first such antibodies capable of binding to living cells. PSMA is an exceptional target present on the cell membrane of all prostate cancer cells and in the blood vessel cells of all solid tumors, but not in normal blood vessels. The lead antibody has been humanized, and 11 clinical trials involving 300 patients have been completed at five academic medical centers.
BZL Biologics' foundational technology is licensed from Cornell University. The antibody technology was developed by a professor at Weill Cornell Medicine.